NEXENTIS TECHNOLOGIES INC. Operating Expenses
NEXENTIS TECHNOLOGIES INC. (NXTS) reported Operating Expenses of $469.76 thousand for the 3-month period ending 2024-09-30, per its 10-Q filed 2024-11-14.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2024-11-14
- NEXENTIS TECHNOLOGIES INC. operating expenses for the quarter ending 2024-09-30 was $469.76K, a 76.26% decline year-over-year.
- NEXENTIS TECHNOLOGIES INC. operating expenses for the quarter ending 2024-06-30 was $302.59K.
- NEXENTIS TECHNOLOGIES INC. operating expenses for the quarter ending 2024-03-31 was $308.72K.
- NEXENTIS TECHNOLOGIES INC. operating expenses for the quarter ending 2023-12-31 was $295.60K.
- NEXENTIS TECHNOLOGIES INC. operating expenses for fiscal 2023 was $2.89M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2024-09-30 | $469.76K 10-Q · filed 2024-11-14 | $772.35K derived: sum of 2 quarters · filed 2024-11-14 | $1.08M 10-Q · filed 2024-11-14 | $1.38M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | $302.59K 10-Q · filed 2024-08-14 | $611.31K 10-Q · filed 2024-08-14 | $906.91K derived: sum of 3 quarters · filed 2024-08-14 | $2.89M derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-03-31 | $308.72K 10-Q · filed 2024-05-15 | $604.32K derived: sum of 2 quarters · filed 2024-05-15 | $2.58M derived: sum of 3 quarters · filed 2024-11-14 | |
| 2023-12-31 | $295.60K derived: 10-K 12 month − 10-Q 9 month · filed 2024-04-01 | $2.27M derived: sum of 2 quarters · filed 2024-11-14 | $2.89M 10-K · filed 2024-04-01 | |
| 2023-09-30 | $1.98M 10-Q · filed 2024-11-14 | $2.59M 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |